Conclusions: These findings identify uPAR as a novel prognostic marker, the FPR as novel therapeutic target in melanoma and suggest that inhibitors of the uPAR84–95/FPR1 interaction may be useful for the treatment of metastatic melanoma. Here, FPR1 is linked to melanoma.